Expression of Progesterone Membrane Receptors in Placentas From Pregnancies Complicated by Intrauterine Growth Restriction: A Prospective Observational Case-Control Study
Data Collection
Collected from today forward - ProspectiveUrogenital Diseases+6
+ Female Urogenital Diseases and Pregnancy Complications
+ Fetal Diseases
Case-Control
Comparing exposures between individuals with and without disease in order to identify potential risk factors.Summary
Study start date: November 1, 2025
Actual date on which the first participant was enrolled.Intrauterine growth restriction (IUGR) remains one of the leading causes of perinatal morbidity and mortality. Although placental insufficiency is considered the major underlying mechanism, the molecular pathways responsible for impaired fetal growth are not fully understood. Progesterone is essential for maintaining pregnancy and exerts its biological effects through both classical nuclear receptors and membrane progesterone receptors. Among these, progesterone receptor membrane component-1 (PGRMC1), progesterone receptor membrane component-2 (PGRMC2), and members of the progestin and adipoQ receptor (PAQR) family have recently attracted attention because of their roles in placental development, angiogenesis, immune regulation, and maintenance of placental integrity. The present study will prospectively recruit women diagnosed with IUGR and healthy pregnant women delivering at the same institution. Placental samples collected immediately after delivery will undergo molecular analysis using quantitative real-time PCR to determine receptor expression levels. Clinical and obstetric characteristics together with neonatal outcomes will be recorded prospectively. The findings may contribute to a better understanding of the molecular mechanisms underlying placental dysfunction in IUGR and may identify potential biomarkers associated with adverse pregnancy outcomes.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.90 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Case-Control
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Female
Biological sex of participants that are eligible to enroll.From 18 to 45 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Samsun University Faculty of Medicine Samsun Training and Research Hospital
Samsun, Turkey (Türkiye)Open Samsun University Faculty of Medicine Samsun Training and Research Hospital in Google Maps